Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron chelation, quo vadis?

Hanspeter Nick1

  • 1Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland. hanspeter.nick@novartis.com

Current Opinion in Chemical Biology
|July 24, 2007
PubMed
Summary
This summary is machine-generated.

Developing new oral iron chelators for transfusional iron overload is challenging. Current options like deferiprone and deferasirox show promise for other iron-related diseases, but new, targeted chelators are needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of cardiac glycoside molecules as inhibitors of c-Myc IRES-mediated translation.

Journal of biomolecular screening·2012
Same author

Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.

Experimental hematology·2012
Same author

Ability of deferasirox to bind iron during measurement of iron.

Clinical chemistry and laboratory medicine·2010
Same author

Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.

Experimental biology and medicine (Maywood, N.J.)·2009
Same author

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

European journal of haematology·2009
Same author

Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.

Acta haematologica·2008

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Orally bioavailable chelators are crucial for managing transfusional iron overload.
  • Since 1962, efforts have focused on developing alternatives to deferoxamine.
  • Market success remains limited to deferiprone and deferasirox due to challenges in achieving oral activity and safety.

Purpose of the Study:

  • To review the development and challenges of oral iron chelators.
  • To explore the potential of existing chelators in new disease indications.
  • To highlight the need for novel, selective chelators.

Main Methods:

  • Literature review of oral iron chelators.
  • Analysis of market-approved drugs (deferiprone, deferasirox).
  • Discussion of off-label applications and future research directions.

Related Experiment Videos

Main Results:

  • Few oral chelators have successfully reached the market.
  • Deferiprone and deferasirox are the only approved oral agents.
  • Existing chelators show potential for treating diseases beyond general iron overload.

Conclusions:

  • Developing effective and safe oral iron chelators is difficult.
  • Current drugs may offer benefits in various iron-related conditions.
  • Tailored, selective chelators are required for specific therapeutic interventions.